Form 4: Vaxcyte CFO Andrew Guggenhime Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Vaxcyte's President and CFO, Andrew Guggenhime, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.
Summary
- Andrew Guggenhime, President and CFO of Vaxcyte, Inc., executed a stock option to acquire 8,000 shares at $5.35 per share on November 18, 2024.
- On the same day, Mr. Guggenhime sold a total of 7,990 shares of common stock in multiple transactions.
- The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 17, 2024.
- The sales were conducted at weighted average prices of $85.595, $86.486 and $87.05 per share.
- Following these transactions, Mr. Guggenhime directly owns 109,491 shares of common stock and 270,827 stock options.
Sentiment
Score: 5
Explanation: The document reflects routine insider trading activity under a pre-arranged plan, which is neither positive nor negative for the company's outlook.
Industry Context
This is a routine filing related to insider trading activity, which is common for executives of publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.
Comparison to Industry Standards
- The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, such as those in the biotechnology sector like Amgen or Regeneron, to manage their personal finances while avoiding potential insider trading issues.
- The reported transactions are typical for executives who receive stock options as part of their compensation package.
- The sale prices are within the range of the current market price for Vaxcyte stock, which is consistent with normal trading activity.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are part of a pre-arranged trading plan and do not indicate a change in the executive's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 05/17/2024 | Date the Rule 10b5-1 trading plan was adopted. |
| 11/18/2024 | Date of the stock option exercise and share sales. |
| 11/19/2024 | Date the Form 4 was signed. |
Keywords
Vaxcyte, Andrew Guggenhime, stock options, share sales, Form 4, 10b5-1 trading plan, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.